Medical journal
Appears in 4 stories · Last updated Nov 2, 2026
Publisher of the RISE UP phase 3 results
The FDA pushed its decision on mitapivat for sickle cell disease from November 1, 2026 to February 1, 2027. On October 9 the agency asked whether the drug needs a risk plan, known as a REMS, to manage safety. Agios sent nine months of extra safety data on October 19; the FDA called that a major amendment on October 28 and added three months to the review.
Updated Nov 2
Published the main study
For years, the only dependable way to grade fatty liver disease has been a needle biopsy: a painful, costly procedure that samples a fraction of the organ. A study of 1,590 patients across 13 countries, published in The Lancet, tested 30 blood and imaging markers against that needle. For cirrhosis and advanced scarring, several matched it. For the earliest stage that drugmakers most want to treat, only one did.
Published the trial and a companion commentary
For more than 30 years, pediatric intensive care doctors have argued over whether turning a desperately ill child face-down, or ventilating them with hundreds of tiny rapid breaths per minute, helps more than standard care. A 424-patient international trial published in The Lancet found neither did.
As of September 2026: Published the LatAm-FINGERS and FINGER trial results
Older adults at risk for dementia improved their thinking 55% more over two years with a coached lifestyle program than with health advice alone. The result comes from LatAm-FINGERS, a 1,065-person trial across 11 Latin American countries, reported July 13 at the Alzheimer's Association International Conference in London and in The Lancet.
Updated Sep 8
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
